Drug Trial News

RSS

Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and efficacy. While ischemic stroke rates were slightly higher, they were not statistically significant, warranting further phase 3 trials for confirmation.

23 Jan 2025

Dapagliflozin and calorie restriction show higher remission rates in type 2 diabetes

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher rates of remission compared with calorie restriction alone, finds a trial published by The BMJ today.

23 Jan 2025

Real-world effectiveness and safety of olaparib in HRD-positive BRCA wild-type ovarian cancer

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy.

23 Jan 2025

New Factor XI inhibitor shows superior safety in treating atrial fibrillation

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to concerns of increased risk of bleeding complications.

22 Jan 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

Study evaluates effectiveness and safety of TMF for chronic hepatitis B

Chronic hepatitis B (CHB) remains a significant global health challenge, and effective antiviral therapies are essential for long-term management.

17 Jan 2025

New clinical trial aims to extend survival for bile duct cancer patients

A new clinical trial, sponsored by UCL and UCLH, aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile of their tumor.

17 Jan 2025

T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.

16 Jan 2025

Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeutic

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial authorization (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802.

15 Jan 2025

Groundbreaking trial finds levofloxacin effective against multidrug-resistant TB

A clinical trial published in the New England Journal of Medicine showed that the oral antibiotic levofloxacin taken once-daily for six months substantially reduced the risk of developing drug-resistant tuberculosis (TB), and almost halved adults' and children's risk of developing multidrug-resistant TB.

15 Jan 2025

Innovative tablet combination shows promise in fighting Trichuris trichiura and other helminths

A new tablet combining albendazole and ivermectin is safe and more effective than albendazole alone in treating Trichuris trichiura and other soil-transmitted helminths (STH), according to a clinical trial conducted by the STOP consortium and led by the Barcelona Institute of Global Health (ISGlobal), a centre supported by "la Caixa" Foundation.

10 Jan 2025

New AI system aims to improve real-world application of clinical trial results

A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a particular therapy being tested in a clinical trial.

8 Jan 2025

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and time-to-progression in patients with locally advanced hepatocellular carcinoma (HCC) when compared to sorafenib alone.

20 Dec 2024

Vanderbilt researchers achieve milestone in Alzheimer's drug development

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a phase I single ascending dose clinical trial of VU319, a drug for memory loss in people with Alzheimer's disease and schizophrenia.

19 Dec 2024

Huntsman Cancer Institute joins innovative clinical trials program for blood cancers

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials program designed to match patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with a clinical trial specifically designed for the genetic signature of their disease.

17 Dec 2024

Pioneering study shows promising results for cognitive treatment in Down syndrome

The ICOD (Improving Condition in Down syndrome) project, a pioneering study in addressing the cognitive difficulties associated with Down syndrome, has demonstrated the safety of treatment with the molecule AEF0217, developed by the French biotech Aelis Farma, as well as its effectiveness in improving cognitive function in these people.

17 Dec 2024

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Drug Trial News

Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients

Dapagliflozin and calorie restriction show higher remission rates in type 2 diabetes

Real-world effectiveness and safety of olaparib in HRD-positive BRCA wild-type ovarian cancer

New Factor XI inhibitor shows superior safety in treating atrial fibrillation

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Study evaluates effectiveness and safety of TMF for chronic hepatitis B

New clinical trial aims to extend survival for bile duct cancer patients

T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients

Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeutic

Groundbreaking trial finds levofloxacin effective against multidrug-resistant TB

Innovative tablet combination shows promise in fighting Trichuris trichiura and other helminths

New AI system aims to improve real-world application of clinical trial results

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients

Vanderbilt researchers achieve milestone in Alzheimer's drug development

Huntsman Cancer Institute joins innovative clinical trials program for blood cancers

Pioneering study shows promising results for cognitive treatment in Down syndrome

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Latest News